Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.

Abstract:

BACKGROUND:Possible relationship between drug exposure and multiple sclerosis (MS) development is insufficiently investigated, and further challenged by the incomplete understanding of MS etiopathogenesis. The study aims to investigate whether drug exposure could contribute to MS, by analyzing worldwide spontaneous reporting archives of adverse drug reaction (ADRs). RESEARCH DESIGN AND METHODS:We retrieved information from the US Food and Drug Administration Adverse Event Reporting System (FAERS) over a 13-year period. Reporting odds ratio (ROR) for MS was calculated for each single substance. Disproportionality signals were considered when at least 10 cases were retrieved with a lower limit of the 95% confidence interval (CI) >1. RESULTS:After a customized data-mining process, 3,226 reports of MS were retrieved. 'Antineoplastic and immunomodulating drugs' (33% of total reports) were the most frequently reported, with 10 disproportionality signals, including etanercept (445 cases; ROR: 2.48; 95% Cl: 2.24-2.74), adalimumab (329; 2.05; 1.83-2.30), and infliximab (119; 2.25; 1.87-2.70). We also observed signals for drugs acting on hormone balance, bone density, and central nervous system. CONCLUSION:Our findings suggest that immunomodulatory drugs increase the risk of MS and point out that some other drug classes should be further investigated for this risk.

journal_name

Expert Opin Drug Saf

authors

Antonazzo IC,Raschi E,Forcesi E,Riise T,Bjornevik K,Baldin E,De Ponti F,Poluzzi E

doi

10.1080/14740338.2018.1506763

subject

Has Abstract

pub_date

2018-09-01 00:00:00

pages

869-874

issue

9

eissn

1474-0338

issn

1744-764X

journal_volume

17

pub_type

杂志文章
  • The cardiac safety of trastuzumab in the treatment of breast cancer.

    abstract:IMPORTANCE OF THE FIELD:Trastuzumab has become a mainstay in the treatment of women with human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer in the metastatic and adjuvant settings. Although trastuzumab is generally well tolerated, cardiac toxicity has emerged as a rare but potentially serious ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740331003627441

    authors: Chien AJ,Rugo HS

    更新日期:2010-03-01 00:00:00

  • Drug-induced parkinsonism.

    abstract:INTRODUCTION:Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease (iPD). Initially reported as a complication of antipsychotics, it was later recognized as a common complication of antidepressants, calcium channel antagonists, gastrointestinal prokinetics,...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.787065

    authors: López-Sendón J,Mena MA,de Yébenes JG

    更新日期:2013-07-01 00:00:00

  • Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients.

    abstract:INTRODUCTION:ACE-inhibitors (ACEI) and diuretics are the typical first-line antihypertensive drugs with complementary mechanisms of action. The present paper is summarizing the evidence supporting the efficacy of their combination in a broad range of hypertensive patients. AREAS COVERED:This source of data is differen...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1836151

    authors: Borghi C,Soldati M,Bragagni A,Cicero AFG

    更新日期:2020-12-01 00:00:00

  • The safety of rosiglitazone in the treatment of type 2 diabetes.

    abstract:BACKGROUND:Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. OBJECTIVES:To ascer...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.7.5.579

    authors: Singh S,Loke YK

    更新日期:2008-09-01 00:00:00

  • Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.

    abstract::Introduction: Patients living with schizophrenia have a marked risk of clinically significant weight gain and obesity compared to the general population. The risks have been highlighted following the introduction of second-generation antipsychotics. In turn, obesity is associated with a higher prevalence of cardiovasc...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1674809

    authors: Marteene W,Winckel K,Hollingworth S,Kisely S,Gallagher E,Hahn M,Ebdrup BH,Firth J,Siskind D

    更新日期:2019-12-01 00:00:00

  • Application of botulinum toxin in pregnancy and its impact on female reproductive health.

    abstract::Introduction: Botulinum toxin (BoNT) is a protein secreted by the anaerobic Gram-negative bacterium Clostridium botulinum. Among the seven known subtypes, type A is the most commonly used in women to treat diseases. It primarily blocks presynaptic release of acetylcholine at the neuromuscular junction, resulting in te...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1707803

    authors: Li W,Tang M

    更新日期:2020-01-01 00:00:00

  • From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.

    abstract:BACKGROUND:To evaluate the safety and tolerability of Polyquad-preserved Travoprost (PQ-Travoprost) in patients previously treated with benzalkonium chloride (BAK)-preserved Latanoprost. METHODS:Cohort 6-month study on open-angle glaucoma or ocular hypertension patients. Complete ophthalmic examination, intraocular pr...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2015.1017467

    authors: Rossi GC,Scudeller L,Rolle T,Pasinetti GM,Bianchi PE

    更新日期:2015-05-01 00:00:00

  • The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.

    abstract::Ixabepilone is a semisynthetic analogue of epothilone B, a novel microtubule-stabilizing agent. Preclinical data suggest that its mechanisms of actions are different from those of the most commonly used microtubule-stabilizing agent, paclitaxel. This information in addition to the cytotoxicity of this drug in taxane-r...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740330802655538

    authors: Gupta D,Mani S

    更新日期:2009-01-01 00:00:00

  • Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China.

    abstract:OBJECTIVE:The aim of this study is to evaluate the safety of cephalosporins, based on utilization and adverse drug events (ADEs). METHODS:This is a retrospective study using data on cephalosporins, obtained from Yangtze River hospital drug information and the Wuhan adverse drug reactions monitoring center database, fr...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,多中心研究

    doi:10.1517/14740338.2012.699037

    authors: Ren X,Liu D,Ding N,Huang K,Xiong Y,Du G,Zeng F

    更新日期:2012-09-01 00:00:00

  • Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.

    abstract:INTRODUCTION:Sulfasalazine (SASP) is a drug commonly used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease (CD) and rheumatoid arthritis (RA). A high incidence of side effects limits therapy with this drug. Getting a wider knowledge of drug pharmacology, indications a...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.529898

    authors: Linares V,Alonso V,Domingo JL

    更新日期:2011-03-01 00:00:00

  • Counterfeit drugs: defining the problem and finding solutions.

    abstract::The problem of counterfeit drugs is increasingly becoming a top priority of drug regulatory agencies, licit pharmaceutical manufacturers and healthcare professionals, and is of rising concern among consumers. A review of the current literature reveals that counterfeiting is no longer isolated in developing nations, bu...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.4.4.619

    authors: Wertheimer AI,Santella TM

    更新日期:2005-07-01 00:00:00

  • Assessment of the quality of medication information for patients in Spain.

    abstract:OBJECTIVE:To analyze the extent to which Spanish leaflets and drug information on the Net met quality criteria. RESEARCH DESIGN AND METHODS:A descriptive study was conducted comparing readability (REA) and comprehensibility (COM) criteria of a random sample of 77 marketed products of the 12 active ingredients most fre...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2013.744965

    authors: Mira JJ,Lorenzo S,Pérez-Jover V,Navarro I,Martín de Rosales AM,Lara C

    更新日期:2013-01-01 00:00:00

  • The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.

    abstract::Stroke is a common cause for morbidity and mortality, causing substantial economic costs. Because thrombosis plays a key role in the pathogenesis of ischaemic stroke, heparins, platelet inhibitors and anticoagulants have been used in stroke management. There were high hopes that patients might benefit from the use of ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740330903150157

    authors: Kiphuth IC,Köhrmann M,Huttner HB,Schellinger PD

    更新日期:2009-09-01 00:00:00

  • Safety of testosterone therapy in men with prostate cancer.

    abstract::Introduction: The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1666103

    authors: Morgentaler A,Caliber M

    更新日期:2019-11-01 00:00:00

  • A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.

    abstract::Worldwide, women comprise > 50% of all people living with HIV and the vast majority of these women are of childbearing age. In fact, a significant proportion of these women are identified as HIV-infected during pregnancy. Preventing perinatal transmission has been one of the greatest prevention successes of the HIV ep...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740330903241584

    authors: Nurutdinova D,Overton ET

    更新日期:2009-11-01 00:00:00

  • Psychiatric symptoms associated with ephedra use.

    abstract::The objective of this review is to describe psychiatric adverse events occurring after ingestion of dietary supplements containing herbal ephedra and to assess the possible relationship between supplement use and the events. The authors reviewed all adverse event reports related to dietary supplements containing herba...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.5.879

    authors: Maglione M,Miotto K,Iguchi M,Hilton L,Shekelle P

    更新日期:2005-09-01 00:00:00

  • A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy.

    abstract:INTRODUCTION:The polycystic ovary syndrome (PCOS) is a very prevalent disorder in premenopausal women. Cardiovascular risk factors cluster in these patients, raising concern about the safety of the drugs commonly used to ameliorate symptoms of androgen excess in in this population at risk of cardiovascular morbidity. ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1839409

    authors: Luque-Ramírez M,Ortiz-Flores AE,Nattero-Chávez L,Escobar-Morreale HF

    更新日期:2020-12-01 00:00:00

  • Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease.

    abstract:INTRODUCTION:Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different ant...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1524869

    authors: Romano S,Buccheri S,Mehran R,Angiolillo DJ,Capodanno D

    更新日期:2018-10-01 00:00:00

  • A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.

    abstract:INTRODUCTION:Regulatory authorities have a legal mandate to implement and maintain a Pharmacovigilance System designed to monitor the safety of authorised medicinal products and detect any change to their risk-benefit balance. Areas covered: This review maps the implementation of pharmacovigilance activities in Malta s...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1247806

    authors: Tanti A,Micallef B,Serracino-Inglott A,Borg JJ

    更新日期:2017-01-01 00:00:00

  • Basiliximab: efficacy and safety evaluation in kidney transplantation.

    abstract:INTRODUCTION:Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. AREAS COVERED:This review eval...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14740338.2014.861816

    authors: Ponticelli C

    更新日期:2014-03-01 00:00:00

  • A safety evaluation of guselkumab for the treatment of psoriasis.

    abstract:INTRODUCTION:Guselkumab is a fully human monoclonal IgG1λ antibody for the treatment of plaque psoriasis that inhibits interleukin (IL)-23p19 subunit, reducing the proliferation of type 17 helper T (Th-17) cells and thus production of Th-17-derived pro-inflammatory cytokines, especially IL-17 and IL-22. Areas covered: ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1488963

    authors: Galluzzo M,D'Adamio S,Campione E,Bianchi L,Talamonti M

    更新日期:2018-07-01 00:00:00

  • Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis.

    abstract:INTRODUCTION:Mood stabilizer (MS) plus antipsychotic (AP) co-treatment is common in patients with acute bipolar disorder (BD), but adverse effects (AEs) of this strategy have not been systematically reviewed. AREAS COVERED:We conducted a systematic review searching PubMed/MEDLINE and PsycINFO on April 1, 2015 for rand...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.1517/14740338.2015.1053457

    authors: Galling B,Garcia MA,Osuchukwu U,Hagi K,Correll CU

    更新日期:2015-08-01 00:00:00

  • The safety of available treatments options for neuroendocrine tumors.

    abstract:INTRODUCTION:Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature to sum...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1354984

    authors: Faggiano A,Lo Calzo F,Pizza G,Modica R,Colao A

    更新日期:2017-10-01 00:00:00

  • The risk of cardiovascular complications with current obesity drugs.

    abstract:INTRODUCTION:Obesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased physical activity in adults. These medications res...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1806234

    authors: Chao AM,Wadden TA,Berkowitz RI,Quigley K,Silvestry F

    更新日期:2020-09-01 00:00:00

  • Osteonecrosis of the jaw: what do bisphosphonates do?

    abstract::Osteonecrosis of the jaw is a new disease, partly caused by bisphosphonates. It is commonly assumed that the bisphosphonates somehow cause cell death (osteocyte necrosis) within the jawbone, which makes it prone to chronic infection. In this article, an alternative pathogenetic theory is suggested, based on the normal...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.5.6.743

    authors: Aspenberg P

    更新日期:2006-11-01 00:00:00

  • Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.

    abstract::The epidemiology, natural history and efficacy of treatment for chronic hepatitis C in children are presented. An increase in the number of vertical infections of this etiology is suggested. In children, especially in those vertically infected, spontaneous elimination of hepatitis C virus (HCV) is observed more often ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2015.1005599

    authors: Pawlowska M

    更新日期:2015-03-01 00:00:00

  • Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.

    abstract::A water soluble derivative of camptothecin, irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC), as well as non-SCLC and gastrointestinal cancers. This extended review of recently concluded and ongoing studies focuses on irinotecan in the treatment of limited (LD) and extensive (ED) SCLC specificall...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.5.2.303

    authors: Kawahara M

    更新日期:2006-03-01 00:00:00

  • The safety of monoclonal antibodies for treatment of colorectal cancer.

    abstract:INTRODUCTION:Monoclonal antibodies such as bevacizumab, ramucirumab, cetuximab and panitumumab play an important role in the treatment of metastatic colorectal cancer (mCRC). With the introduction of these drugs considerable improvements in both progression-free survival (PFS) and overall survival (OS) were achieved. H...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2016.1167186

    authors: Berger MD,Lenz HJ

    更新日期:2016-06-01 00:00:00

  • Examining the safety of amiodarone.

    abstract:INTRODUCTION:Amiodarone is the most widely used antiarrhythmic agent, with demonstrated effectiveness against all the spectrum of cardiac tachyarrhythmias. The risk of adverse effects acts as a limiting factor to its utilization especially in the long term. This article systematically reviews the published evidence on ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2012.660915

    authors: Santangeli P,Di Biase L,Burkhardt JD,Bai R,Mohanty P,Pump A,Natale A

    更新日期:2012-03-01 00:00:00

  • Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects.

    abstract:INTRODUCTION:The goal of antiviral therapy in patients with chronic hepatitis C is to slow or halt the progression of fibrosis and prevent the development of cirrhosis. Accordingly, antiviral treatment is proposed for a large population of patients with chronic hepatitis. AREAS COVERED:The standard-of-care for chronic...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.559161

    authors: Calvaruso V,Mazza M,Almasio PL

    更新日期:2011-05-01 00:00:00